Pando HEY, Miló VCA, Díaz FMF, Herrera SA, Díaz AH

Language: Spanish
References: 12
Page: 139-147
PDF size: 389.15 Kb.

ABSTRACT

Introduction: chronic obstructive pulmonary disease is a preventable and treatable disease, generally progressive and associated with an abnormal inflammatory response of the lungs to harmful particles or gases, produced mainly by smoking. It primarily affects the lungs, but also produces significant systemic consequences.
Objective: to characterize the clinical and epidemiological characteristics of patients with acute exacerbation of chronic obstructive pulmonary disease in the Internal Medicine Service at "Dr. León Cuervo Rubio" Provincial General Teaching Hospital, during the year 2017.
Method: an observational, descriptive and cross-sectional study was carried out, with 281 hospitalized patients with acute exacerbation of the disease. The information was collected from the patient's medical records. The ethical principles were observed.
Results: the highest frequency of chronic obstructive pulmonary disease occurred in the age group between 78-87 years (63,50 %), predominantly male gender (70,9 %); 62,27 % smoked at the time of the study. The disease that constituted the most frequent comorbidity was hypertension with 61,4 %. The main cause of admission was the increase in dyspnea with 91,0 %. Regarding treatment at discharge, it was observed that the most commonly used drugs were short-acting antibiotics and bronchodilators (90,2 %).
Conclusions: smoking is significantly associated with chronic obstructive pulmonary disease, where the increase in dyspnea is the critical symptom of its exacerbation; the comorbidity that most affected this condition was hypertension. Short-acting antibiotics and bronchodilators were the most indicated drugs at discharge.

REFERENCES

1. Johannessen A, Omenaas E, Bakke P, Gulsvik A. Incidence of GOLD-defined chronic obstructive pulmonary disease in a general adult population. int j tuberc lung dis [Internet]. 2015 [citado 2017 Dic 19]; 9(8): 926-932. Disponible en: http://www.ingentaconnect.com/content/iuatld/ijtld/2005/00000009/00000008/art00018

2. Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafakas N. Prevalence of COPD in Greece. Chest [Internet]. 2004 [citado 2017 Dic 19]; 125(3): 892-900. Disponible en: https://www.sciencedirect.com/science/article/pii/S0012369215319255

3. González J, Marín M, Sánchez-Salcedo P, Zulueta JJ. Lung cancer screening in patients with chronic obstructive pulmonary disease. Ann Transl Med [Internet]. 2016 [citado 2017 Dic 19]; 4(8): 160. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860483/

4. Breen D, Churches T, Hawker F, Torzillo PJ. Acute respiratory failure secondary to chronic obstructive pulmonary disease treated in the intensive care unit: a long term follow up study. Thorax [Internet]. 2013 [citado 2017 Dic 19]; 57(1): 29–33. Disponible en: http://thorax.bmj.com/content/57/1/29.short

5. Solanes I, Casan P, Sangenis M, Calaf N, Giraldo BGR. Factores de riesgo de mortalidad en la EPOC. Arch Bronconeumol [Internet]. 2014 [citado 2017 Dic 19]; 43(8): 445-9. Disponible en: http://www.sciencedirect.com/science/article/pii/S0300289607711055

6. López Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology [Internet]. 2016 [citado 2017 Dic 19]; 21: 14–23. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1111/resp.12660

7. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med [Internet]. 2015 [citado 2017 Dic 19]; 3(8): 631-9. Disponible en: http://www.sciencedirect.com/science/article/pii/S2213260015002416

8. Pavasini R, D’Ascenzo F, Campo G, Biscaglia S, Ferri A, Contoli M, et al. Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and metaanalysis. Int J Cardiol. [Internet]. 2015 [citado 2017 Dic 19]; 191(15): 187-93. Disponible en: http://www.sciencedirect.com/science/article/pii/S0167527315010232

9. Grosdidier S, Ferrer A, Faner R, Piñero J, Roca J, Cosío B, et al. Network medicine analysis of COPD multimorbidities. Respir Res. [Internet]. 2014 [citado 2017 Dic 19]; 15: 111. Disponible en: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-014-0111-4

10. Garin N, Koyanagi A, Chatterji S, Tyrovolas S, Olaya B, Leonardi M, et al. Global Multimorbidity Patterns: A Cross-Sectional, Population-Based, Multi-Country Study. J Gerontol A BiolSciMedSci. [Internet]. 2016 [citado 2017 Dic 19]; 71(2): 205-14. Disponible en: https://academic.oup.com/biomedgerontology/article/71/2/205/2605626

11. Kohansal R, Martinez C P, Agusti A, Buist AS. The Natural History of Chronic Airflow Obstruction Revisited: An Analysis of the Framingham Offspring Cohort. Am J Respir Crit Care Med [Internet]. 2009 [citado 2017 Dic 19]; 180(1):3-10. Disponibleen: http://www.atsjournals.org/doi/abs/10.1164/rccm.200901-0047OC

12. Esteban C, Quintana JM, Aburto M, Moraza J, Capelastegui A. A simple score for assessing stable chronic obstructive pulmonary disease. QJM [Internet]. 2006 [citado 2017 Dic 19]; 99(11): 751-928. Disponible en: https://academic.oup.com/qjmed/article/99/11/751/2261128